Vaxcyte Corporate Presentation

Limitations of Current PCVS Coverage Expansion Needed to Address Circulating Disease, but Protein Carrier Backbone Problematic о 60 60 50 40 40 30 30 Limitations of Conventional Chemistry Random conjugation Higher ratio of protein carrier to polysaccharide Further exacerbates carrier suppression Protein Carrier (ug) ■Serotype Coverage (#) 34 51 554 10 210 20 20 20 20v 13v 7v 0 Prevnar 7 Prevnar 13 Pfizer 20v 16 (1) Prevnar 20 BLA Clinical Review Memorandum. STN: 125731/0 June 8, 2021.

View entire presentation